Continuing Medical Education at THT 2024

Given the growing prevalence of heart failure worldwide, we recognize a clear mandate for developing new monitoring strategies and treatment options to increase survival, decrease hospitalizations, and improve quality of life — and for achieving these goals via a variety of potential interventions that target the various contributors to heart failure.

Technology and Heart Failure Therapeutics (THT) 2024 is the conference that focuses on device- and technology-based treatments, while putting these into the perspective of drug-based therapies, thus filling existing gaps.

Covering a full range of updates on the current status of drug- and device-based treatments for heart failure across the spectrum, LV ejection fractions, and late-breaking pivotal studies that have not yet appeared in publications or in treatment guidelines, THT 2024 is an immersive experience in the latest innovations that practitioners can put into practice for treating heart failure.

Concomitantly, with unlimited opportunities for learning and global engagement, THT 2024 offers a future-oriented view of the pipeline for heart failure therapeutics, with a focus on technologies (drugs, devices, monitoring strategies) that are currently in development and in clinical trials — as well as an overview of the rapid advances in artificial intelligence and machine learning and how these technologies will transform the care of heart failure patients in the near future.

By the end of this course, attendees should be able to:

• Recount an up-to-date review of the current standards for the care of patients with heart failure across the spectrum of ejection fractions, etiologies and disease severities.
• Understand the results of recently conducted studies of heart failure therapies (devices and drugs) that have not yet been incorporated into heart failure guidelines.
• Understand the different types of monitoring and therapeutic devices that are currently under development for patients with acute and chronic heart failure and the status of ongoing clinical trials.
• Understand how big data, artificial intelligence, machine learning and data-security matters are being incorporated into the management of heart failure patients.

THT 2024 is designed for a multidisciplinary audience that includes anyone interested in heart failure management and a comprehensive overview of existing and investigational interventions. This includes:

• Heart failure specialists (fellows, nurses, physicians, physician assistants, and research coordinators)
• Cardiac imaging specialists
• Cardiac and vascular surgeons
• Clinical cardiologists
• Fellows in interventional cardiovascular medicine and related fields
• Industry professionals
• Interventional cardiologists
• Medical device experts
• Nurse practitioners
• Physician assistants
• Research scientists

In accordance with accredited continuing education sponsored by CRF, all planners, teachers, and authors with control over activity content are required to disclose to the provider all financial relationships with ineligible companies within the last 24 months. Accredited providers are required to provide this information to learners before the start of an activity.

Discussion of off-label product use during live cases is made at the sole discretion of the faculty. Off-label product discussion and usage are not endorsed by the Cardiovascular Research Foundation or the conference directors of this activity.

The Cardiovascular Research Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Cardiovascular Research Foundation designates this live activity for a maximum of 16 AMA PRA Category 1 Credits™ for physicians attending THT 2024. Physicians can claim credit commensurate with the extent of their participation in the activity.

Documentation of awarded credit is provided for registered attendees in exchange for completed activity evaluations. CME, MOC, and Certificate of Attendance can be claimed through the CRF Events App (available via the iOS App Store or the Google Play Store) or the CRF CME Portal.

Participants will earn MOC points equivalent to the number of CME credits claimed for the activity. Successful completion of this CME activity enables the participant to earn up to 16 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting American Board of Internal Medicine (ABIM) MOC points.

As a CME provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), CRF is committed to ensuring balance, independence, objectivity, and scientific rigor in all its sponsored programs. Commercial support from industry does not influence educational content, faculty selection, and/or faculty presentations, and therefore, does not compromise the scientific integrity of the educational activity.

The CRF independent reviewers are Grzegorz Kaluza, MD, PhD; Gary S. Mintz, MD; and Donald E. Cutlip, MD.

• Gary S. Mintz, MD — Consultant Fee/Honoraria/Speaker's Bureau - Boston Scientific Corporation; Abbott; SpectraWave; Gentuity.
• Grzegorz L. Kaluza, MD, PhD — Grant Support/Research Contract - 4C Medical; Terumo Medical Corporation; Bristol-Myers Squibb; Edwards Lifesciences; Advanced Nano Technologies; Adriakaim; Reflow Medical; Tenaya Therapeutics; Shape Memory Medical; Occlutech; Neochord; MicroInterventional Devices; Lungpacer; Inozyme; InnovHeart; HLT; Deinde Medical; Ancora Heart; Cardiac Implants; Dura Biotech; Soundbite Medical Solutions; Mitria; InQB8; Ethicon; R3 Vascular; Puzzle Medical; ReCardia; StrideBio; VivaSure; Magenta Medical; Canon; Thubrikar Aortic Valve; Cardiovascular Systems, Inc.; Acotec Scientific; Microbot; Philips; Zoll; Cook Medical; Medtronic; ReValve Medical; Orchestra Biomed; Microtech; Motus GI; MicroVention; Takeda Pharmaceuticals; Hydrocision; Encompass Technologies; Retriever Medical; Siemens Healthineers; Trisol Medical; IntraTech; Abbott; Bayliss Medical; Dropshot Therapeutics; Abiomed; Autonomix; UltraVet; Meacor; AMX Medical; JensCare.
• Donald Cutlip, MD — Nothing to disclose.

• Please complete the daily THT 2024 session evaluations on the CRF Events App (available via the iOS App Store or the Google Play Store) or at the CRF CME Portal.
• Claim credit commensurate with the extent of your participation in the activity.
• After completing the evaluation summary, your Continuing Medical Education (CME) or Certificate of Attendance will be generated on the screen for you to save or print.
• Alternatively, by request, we can email your documentation to you. Please send your request to [email protected].

How do I earn ABIM MOC points?

CRF offers American Board of Internal Medicine Maintenance of Certification for select sessions, designed within the ABIM framework. During sessions offering MOC points, you must actively participate and complete the short session evaluation.

Who can claim ABIM MOC points?

Any appropriately badged meeting registrant can attend MOC-accredited sessions, but only ABIM diplomates are eligible to claim MOC points.

How do I claim ABIM MOC points?

Claim your points in the CRF CME portal. First, complete the online evaluation form for each session. Then you will need to enter your ABIM diplomate number, birth date, and state license number. Your MOC points will be registered and transferred to ABIM. You can claim your ABIM MOC points only once for each eligible session.

After submission, when will I see my MOC points in my ABIM physician portal?

It may take up to 72 hours for your MOC points to be posted. Also check to be sure that you entered your correct diplomate number, birthdate, and state license number. Incorrect entries will create a significant delay in processing your points.

For inquiries about CME, MOC, or Certificate of Attendance, or to claim credits for a previous conference,please contact us at [email protected].